Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Fights Problems With Pre-ANDA Meeting Requests

More Pre-ANDA Meeting Requests Are Being Denied

Executive Summary

More meeting requests are being denied because the sponsor's pre-meeting package was incomplete, the agency said.

You may also be interested in...



Generic Drug Assessment Times Show Improvement In GDUFA Performance Report

Averages likely will increase as more of the cohort is approved, however.

FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.

Unhappy With GDUFA II? Note It For GDUFA III, FDA Says

US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel